{"id":745532,"date":"2017-06-05T06:05:00","date_gmt":"2017-06-05T06:05:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/"},"modified":"2025-11-07T01:26:26","modified_gmt":"2025-11-07T06:26:26","slug":"new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/","title":{"rendered":"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer"},"content":{"rendered":"<p class=\"bwalignc\">       Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in        Patients with Locally Advanced Triple-Negative (TNBC) and Hormone        Receptor-Positive\/HER2-Negative (HR+\/HER2-) Breast Cancers     <\/p>\n<\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      QuantumLeap Healthcare Collaborative, today announced results from the<br \/>\n      Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with standard<br \/>\n      therapy [paclitaxel followed by doxorubicin and cyclophosphamide (AC)]<br \/>\n      as a neoadjuvant (pre-operative) treatment for patients with locally<br \/>\n      advanced triple-negative breast cancer (TNBC) or hormone<br \/>\n      receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer. Findings<br \/>\n      showed that the addition of KEYTRUDA increased the estimated pathologic<br \/>\n      complete response (pCR) rate nearly threefold in patients with TNBC (60%<br \/>\n      vs 20%) and in patients with HR+\/HER2- breast cancer (34% vs 13%)<br \/>\n      compared to standard therapy. Overall, based on Bayesian predictive<br \/>\n      probability of success in a confirmatory Phase 3 trial, KEYTRUDA has<br \/>\n      graduated from the I-SPY 2 TRIAL for all signatures in which it was<br \/>\n      tested (TNBC, all HER2-, and HR+\/HER2-). Data will be presented today by<br \/>\n      Dr. Rita Nanda, The University of Chicago, during an oral session at the<br \/>\n      2017 American Society of Clinical Oncology (ASCO) Annual Meeting in<br \/>\n      Chicago (Abstract #506) and will also be presented in subsequent \u201cBest<br \/>\n      of ASCO\u201d events scheduled throughout the year.\n    <\/p>\n<p>\n      \u201cKEYTRUDA in combination with standard therapy tripled the rate of<br \/>\n      pathologic complete responses in HER2- patients in the I-SPY 2 Trial,\u201d<br \/>\n      said Laura J. Esserman, M.D., MBA, professor of surgery and radiology<br \/>\n      and director of the Carol Franc Buck Breast Care Center at UCSF Helen<br \/>\n      Diller Family Comprehensive Cancer Center, and the overall principal<br \/>\n      investigator for the I-SPY TRIALS. \u201cThe regimen indicates a new and<br \/>\n      important treatment pathway and gives us well-grounded hope for new<br \/>\n      options for patients with these aggressive breast cancers \u2013 and that\u2019s<br \/>\n      potentially very good news.\u201d\n    <\/p>\n<p>\n      \u201cWe recognize that there is a critical unmet need for patients with<br \/>\n      certain breast cancer subtypes and believe that combination regimens<br \/>\n      will be important to advancing patient care,\u201d said Dr. Eric Rubin, vice<br \/>\n      president of early-stage development, clinical oncology, Merck Research<br \/>\n      Laboratories. \u201cThe results presented at ASCO, which add to the growing<br \/>\n      body of evidence for KEYTRUDA in various types of breast cancer, are<br \/>\n      exciting and demonstrate the potential benefit of KEYTRUDA in these<br \/>\n      patients.\u201d\n    <\/p>\n<p>\n      The I-SPY 2 TRIAL (NCT01042379), sponsored by QuantumLeap Healthcare<br \/>\n      Collaborative, is a standing Phase 2 randomized, controlled,<br \/>\n      multi-center trial for women with newly diagnosed, locally advanced<br \/>\n      breast cancer (Stage II\/III), and is designed to screen promising new<br \/>\n      treatments and identify which therapies are most effective in specific<br \/>\n      patient subgroups based on molecular characteristics (biomarker<br \/>\n      signatures). The trial is an adaptive study design assessing the<br \/>\n      combination of biologically targeted investigational drugs with standard<br \/>\n      chemotherapy in the neoadjuvant setting, compared to standard<br \/>\n      chemotherapy alone. The primary endpoint is to determine whether the<br \/>\n      combination of certain therapies increases the probability of pCR in the<br \/>\n      breast and the lymph nodes at the time of surgery. The data presented at<br \/>\n      ASCO from the I-SPY 2 TRIAL were based on results observed in patients<br \/>\n      at high risk of relapse using up-front tumor profiling (including HR<br \/>\n      status, HER2 status, and the MammaPrint 70-gene signature test).<br \/>\n      Patients were treated with weekly standard chemotherapy (paclitaxel) for<br \/>\n      12 weeks, with or without KEYTRUDA (pembrolizumab), followed by<br \/>\n      doxorubicin and cyclophosphamide (AC) every 3 weeks for four cycles.<br \/>\n      Sixty-nine patients were adaptively randomized to receive KEYTRUDA in<br \/>\n      the trial from December 2015 until it graduated in November 2016. In<br \/>\n      total, 46 patients have undergone surgery; the other 23 have on-therapy<br \/>\n      MRI assessments.\n    <\/p>\n<p>\n      In patients with TNBC, an absolute increase in the estimated pCR rate of<br \/>\n      40 percent was observed in the KEYTRUDA arm (based on the estimated pCR<br \/>\n      rate of 60% with KEYTRUDA plus standard therapy compared to 20% with<br \/>\n      standard therapy alone). In patients with HER2- breast cancer, an<br \/>\n      absolute increase in the estimated pCR rate of 30 percent was observed<br \/>\n      in the KEYTRUDA arm (based on the estimated pCR rate of 46% with<br \/>\n      KEYTRUDA plus standard therapy compared to 16% with standard therapy<br \/>\n      alone). In patients with HR+\/HER2- breast cancer, an absolute increase<br \/>\n      in the estimated pCR rate of 21 percent was observed in the KEYTRUDA<br \/>\n      (pembrolizumab) arm (based on the estimated pCR rate of 34% with<br \/>\n      KEYTRUDA plus standard therapy compared to 13% with standard therapy<br \/>\n      alone). The Bayesian model estimated pCR rates appropriately adjust to<br \/>\n      characteristics of the I-SPY 2 population, including MammaPrint status.\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"5\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignm bwalignl bwsinglebottom\" rowspan=\"2\">\n          <b>Signature<\/b>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" colspan=\"5\">\n          <b>Estimated pCR Rate<\/b><\/p>\n<p class=\"bwcellpmargin\">\n            <b>(95% Probability Interval)<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>Probability<\/b><br \/>\n<br \/>\n<b>KEYTRUDA Is<\/b><br \/>\n<br \/>\n<b>Superior to<\/b><br \/>\n<br \/>\n<b>Control<\/b>\n          <\/p>\n<\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\n            <b>Predictive<\/b><br \/>\n<br \/>\n<b>Probability of<\/b><br \/>\n<br \/>\n<b>Success in<\/b><br \/>\n<br \/>\n<b>Phase<br \/>\n            3<\/b>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>KEYTRUDA <\/b><br \/>\n<br \/>\n<b>Plus Standard Therapy<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignm bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            <b>Standard<\/b><br \/>\n<br \/>\n<b>Therapy Alone<\/b>\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>TNBC<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.60<\/p>\n<p class=\"bwcellpmargin\">\n            (0.43 \u2013 0.78)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.20<\/p>\n<p class=\"bwcellpmargin\">\n            (0.06 \u2013 0.33)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &gt;99%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &gt;99%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>All HER2-<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.46<\/p>\n<p class=\"bwcellpmargin\">\n            (0.34 \u2013 0.58)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.16<\/p>\n<p class=\"bwcellpmargin\">\n            (0.06 \u2013 0.27)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &gt;99%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n          99%\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\">\n          <b>HR+\/HER2-<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.34<\/p>\n<p class=\"bwcellpmargin\">\n            (0.19 \u2013 0.48)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          0.13<\/p>\n<p class=\"bwcellpmargin\">\n            (0.03 \u2013 0.24)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          &gt;99%\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            88%\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies across tumors. In the KEYTRUDA arm, Grade<br \/>\n      3-5 treatment-related adverse events include diarrhea (n=5), febrile<br \/>\n      neutropenia (n=5), fatigue (n=4), anemia (n=3), nausea (n=3),<br \/>\n      neutropenia without fever (n=1), peripheral motor neuropathy (n=1),<br \/>\n      peripheral sensory neuropathy (n=1) and vomiting (n=1). Immune-mediated<br \/>\n      adverse events of Grade 3-5 include adrenal insufficiency (n=5),<br \/>\n      hepatitis (n=2), colitis (n=1) and hypothyroidism (n=1). Five of six<br \/>\n      patients presented with adrenal insufficiency after completion of AC<br \/>\n      (21-24 weeks after starting KEYTRUDA), and one presented during KEYTRUDA<br \/>\n      treatment (5 weeks after starting KEYTRUDA).\n    <\/p>\n<p>\n      \u201cNot all breast cancers are the same \u2013 and there has continued to be a<br \/>\n      significant gap in the treatment options available for patients with<br \/>\n      certain subtypes, particularly TNBC,\u201d said Dr. Rita Nanda, medical<br \/>\n      oncologist at The University of Chicago. \u201cThe results observed in this<br \/>\n      trial are not only encouraging, but demonstrate the potential for<br \/>\n      treatment combinations that can make a difference in patient outcomes.\u201d\n    <\/p>\n<p>\n      <b>About I-SPY and the I-SPY 2 TRIAL<\/b>\n    <\/p>\n<p>\n      The I-SPY (Investigation of Serial Studies to Predict Your Therapeutic<br \/>\n      Response with Imaging And moLecular Analysis) TRIAL is conducted by a<br \/>\n      consortium that brings together the U.S. Food and Drug Administration<br \/>\n      (FDA), leading academic medical centers, and patient advocates, as well<br \/>\n      as Merck and other pharmaceutical and biotech companies.\n    <\/p>\n<p>\n      The I-SPY 2 TRIAL is a collaborative effort among academic investigators<br \/>\n      from 20 major cancer research centers across the U.S. and QuantumLeap<br \/>\n      Healthcare Collaborative, the FDA, and the Foundation for the National<br \/>\n      Institutes of Health (FNIH) Cancer Biomarkers Consortium. Major<br \/>\n      supporters include The Safeway Foundation and the Bill Bowes Foundation.\n    <\/p>\n<p>\n      The I-SPY 2 TRIAL\u2019s adaptive statistical design was developed by the<br \/>\n      pioneering principal investigators for the I-SPY trial, Laura J.<br \/>\n      Esserman, M.D., MBA, and Donald A. Berry, Ph.D., professor of<br \/>\n      biostatistics at The University of Texas MD Anderson Cancer Center and<br \/>\n      founder of Berry Consultants in collaboration with the FDA, industry,<br \/>\n      and many leading academic collaborators including the Agents working<br \/>\n      group chair (Doug Yee, M.D. from the University of Minnesota) and the<br \/>\n      Trial Operations working group chair (Angie DeMichele, M.D. from the<br \/>\n      University of Pennsylvania). The trial is a unique collaborative effort<br \/>\n      where over 50 clinicians are actively engaged in the conduct of the<br \/>\n      trial.\n    <\/p>\n<p>\n      The I-SPY 2 TRIAL adaptive-trial design is based on Bayesian predictive<br \/>\n      probability that a biological regimen will be shown to be statistically<br \/>\n      superior to standard therapy in an equally randomized 300-patient<br \/>\n      confirmatory trial. Regimens that have a high Bayesian predictive<br \/>\n      probability of showing superiority in at least one of 10 predefined<br \/>\n      signatures graduate from the trial. Regimens are dropped for futility if<br \/>\n      they show a low predictive probability of showing superiority over<br \/>\n      standard therapy in all 10 signatures. A maximum total of 120 patients<br \/>\n      can be assigned to each experimental regimen. A regimen can graduate<br \/>\n      early and at any time after having 60 patients assigned to it.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 500 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is administered as an intravenous infusion over<br \/>\n      30 minutes every three weeks for the approved indications. KEYTRUDA for<br \/>\n      injection is supplied in a 100 mg single-dose vial.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA is administered at a fixed dose of 200 mg<br \/>\n      every three weeks until disease progression, unacceptable toxicity, or<br \/>\n      up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with<br \/>\n      recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)<br \/>\n      with disease progression on or after platinum-containing chemotherapy.<br \/>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA is also indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who have disease progression<br \/>\n      during or following platinum-containing chemotherapy or within 12 months<br \/>\n      of neoadjuvant or adjuvant treatment with platinum-containing<br \/>\n      chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is indicated for the treatment of adult and<br \/>\n      pediatric patients with unresectable or metastatic microsatellite<br \/>\n      instability-high (MSI-H) or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 or<br \/>\n      recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA (pembrolizumab), including Grade 2<br \/>\n      (0.2%), 3 (0.3%), and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs<br \/>\n      and symptoms of hypophysitis (including hypopituitarism and adrenal<br \/>\n      insufficiency). Administer corticosteroids and hormone replacement as<br \/>\n      clinically indicated. Withhold KEYTRUDA for Grade 2; withhold or<br \/>\n      discontinue for Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. Thyroiditis occurred in 16 (0.6%) of 2799 patients<br \/>\n      receiving KEYTRUDA, including Grade 2 (0.3%) thyroiditis. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer replacement hormones for hypothyroidism and manage<br \/>\n      hyperthyroidism with thionamides and beta-blockers as appropriate.<br \/>\n      Withhold or discontinue KEYTRUDA for Grade 3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), exfoliative dermatitis, bullous pemphigoid, rash<br \/>\n      (1.4%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia gravis,<br \/>\n      vasculitis, pancreatitis, hemolytic anemia, and partial seizures arising<br \/>\n      in a patient with inflammatory foci in brain parenchyma. In addition,<br \/>\n      myelitis and myocarditis were reported in other clinical trials,<br \/>\n      including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA (pembrolizumab). Treatment with KEYTRUDA may increase the<br \/>\n      risk of rejection in solid organ transplant recipients. Consider the<br \/>\n      benefit of treatment with KEYTRUDA vs the risk of possible organ<br \/>\n      rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      on any trial, 6 patients (26%) developed graft-versus-host-disease<br \/>\n      (GVHD), one of which was fatal, and 2 patients (9%) developed severe<br \/>\n      hepatic veno-occlusive disease (VOD) after reduced-intensity<br \/>\n      conditioning, one of which was fatal. Cases of fatal hyperacute GVHD<br \/>\n      after allogeneic HSCT have also been reported in patients with lymphoma<br \/>\n      who received a PD-1 receptor\u2013blocking antibody before transplantation.<br \/>\n      These complications may occur despite intervening therapy between PD-1<br \/>\n      blockade and allogeneic HSCT. Follow patients closely for early evidence<br \/>\n      of transplant-related complications such as hyperacute GVHD, severe<br \/>\n      (Grade 3 to 4) acute GVHD, steroid-requiring febrile syndrome, hepatic<br \/>\n      VOD, and other immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA (pembrolizumab)<br \/>\n      vs ipilimumab were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA),<br \/>\n      rash (24% vs 23%), and nausea (21% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for ipilimumab only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-002, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      12% of 357 patients with advanced melanoma; the most common (\u22651%) were<br \/>\n      general physical health deterioration (1%), asthenia (1%), dyspnea (1%),<br \/>\n      pneumonitis (1%), and generalized edema (1%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 14% of patients; the most common<br \/>\n      (\u22651%) were dyspnea (1%), diarrhea (1%), and maculopapular rash (1%). The<br \/>\n      most common adverse reactions with KEYTRUDA vs chemotherapy were fatigue<br \/>\n      (43% with KEYTRUDA), pruritus (28% vs 8%), rash (24% vs 8%),<br \/>\n      constipation (22% vs 20%), nausea (22% with KEYTRUDA), diarrhea (20% vs<br \/>\n      20%), and decreased appetite (20% with KEYTRUDA). Corresponding<br \/>\n      incidence rates are listed for chemotherapy only for those adverse<br \/>\n      reactions that occurred at the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA occurred in 39% of patients; the most common<br \/>\n      (\u22652%) were fatigue (8%), neutrophil count decreased (8%), anemia (5%),<br \/>\n      dyspnea (3.4%), and pneumonitis (3.4%).The most common adverse reactions<br \/>\n      (\u226520%) with KEYTRUDA compared to carbo\/pem alone were fatigue (71% vs<br \/>\n      50%), nausea (68% vs 56%), constipation (51% vs 37%), rash (42% vs 21%),<br \/>\n      vomiting (39% vs 27%), dyspnea (39% vs 21%), diarrhea (37% vs 23%),<br \/>\n      decreased appetite (31% vs 23%), headache (31% vs 16%), cough (24% vs<br \/>\n      18%), dizziness (24% vs 16%), insomnia (24% vs 15%), pruritus (24% vs<br \/>\n      4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs 11%), alopecia<br \/>\n      (20% vs 3.2%), upper respiratory tract infection (20% vs 3.2%), and<br \/>\n      arthralgia (15% vs 24%). This study was not designed to demonstrate a<br \/>\n      statistically significant difference in adverse reaction rates for<br \/>\n      KEYTRUDA (pembrolizumab) as compared to carbo\/pem alone for any<br \/>\n      specified adverse reaction.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients<br \/>\n      with cHL, and treatment was interrupted due to adverse reactions in 26%<br \/>\n      of patients. Fifteen percent (15%) of patients had an adverse reaction<br \/>\n      requiring systemic corticosteroid therapy. Serious adverse reactions<br \/>\n      occurred in 16% of patients. The most frequent serious adverse reactions<br \/>\n      (\u22651%) included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and<br \/>\n      herpes zoster. Two patients died from causes other than disease<br \/>\n      progression; one from GVHD after subsequent allogeneic HSCT and one from<br \/>\n      septic shock. The most common adverse reactions (occurring in \u226520% of<br \/>\n      patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in \u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA occurred in 22% of<br \/>\n      patients; the most common (\u22651%) were liver enzyme increase, diarrhea,<br \/>\n      urinary tract infection, acute kidney injury, fatigue, joint pain, and<br \/>\n      pneumonia. Serious adverse reactions occurred in 42% of patients, the<br \/>\n      most frequent (\u22652%) of which were urinary tract infection, hematuria,<br \/>\n      acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (\u226520%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA<br \/>\n      (pembrolizumab)-treated patients, the most frequent (\u22652%) of which were<br \/>\n      urinary tract infection, pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue, pruritus, diarrhea, decreased appetite, rash, pyrexia, cough,<br \/>\n      dyspnea, musculoskeletal pain, constipation, and nausea.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>About QuantumLeap Healthcare Collaborative<\/b>\n    <\/p>\n<p>\n      QuantumLeap Healthcare Collaborative, a non-profit foundation, was<br \/>\n      established in 2005 as a collaboration between medical researchers at<br \/>\n      University of California at San Francisco, and Silicon Valley<br \/>\n      entrepreneurs. QuantumLeap\u2019s mission is to accelerate transfer of<br \/>\n      high-impact research in clinical processes and systems technology into<br \/>\n      widespread adoption so that patients and physicians can benefit from the<br \/>\n      research as soon as practicable. QuantumLeap provides operational,<br \/>\n      financial and regulatory oversight to I-SPY. For more information,<br \/>\n      visit: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.quantumleaphealth.org&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.quantumleaphealth.org&amp;index=1&amp;md5=008e6dbb18745d92528e42d0f81e3d94\" rel=\"nofollow\">http:\/\/www.quantumleaphealth.org<\/a>.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program that includes more than 500 clinical trials evaluating<br \/>\n      our anti-PD-1 therapy across more than 30 tumor types. We also continue<br \/>\n      to strengthen our immuno-oncology portfolio through strategic<br \/>\n      acquisitions and are prioritizing the development of several promising<br \/>\n      immunotherapeutic candidates with the potential to improve the treatment<br \/>\n      of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=1bfa3ce1d1bca81692fa875f9ada86b0\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=013e9910be39c931934b0e65ec974ee5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=efb689c39012074907dc321757daef83\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=5d2bd65af0f59b06b0cb949fdd29717a\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=aebb3e285ccb1431aca31c529c0357ca\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=6f6e7fc1ea17c2be462cfb2b00dd1755\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=52d7c4818c5d7c2c4142d3f31cced152\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=2c51321b0fe42a4d4728fdc31a42510c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=10&amp;md5=728ff8a292a04c3b2cb333e0984866f1\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b>\n    <\/p>\n<p>\n      <b>Patient Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51569430&amp;newsitemid=20170605005510&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=11&amp;md5=c1d8e3eeeef8ce35418d1a09968e7800\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170605005510r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Merck<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Merck<br \/>Ann        Bush, 908-740-6677<br \/>or<br \/>King + Company for QuantumLeap<br \/>Caren        Browning, 212-561-7464<br \/>or<br \/>Investors:<br \/>Teri Loxam,        908-740-1986<br \/>or<br \/>Amy Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive\/HER2-Negative (HR+\/HER2-) Breast Cancers Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced results from the Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with standard therapy [paclitaxel followed by doxorubicin and cyclophosphamide (AC)] as a neoadjuvant (pre-operative) treatment for patients with locally advanced triple-negative breast cancer (TNBC) or hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer. Findings showed that the addition of KEYTRUDA increased the estimated pathologic complete response (pCR) rate nearly threefold in patients with TNBC (60% vs 20%) and in patients with HR+\/HER2- breast cancer (34% vs 13%) compared to standard therapy. Overall, based on Bayesian<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[149,53,64,55,289],"class_list":["post-745532","news_item","type-news_item","status-publish","hentry","tag-asco","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive\/HER2-Negative (HR+\/HER2-) Breast Cancers Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced results from the Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with standard therapy [paclitaxel followed by doxorubicin and cyclophosphamide (AC)] as a neoadjuvant (pre-operative) treatment for patients with locally advanced triple-negative breast cancer (TNBC) or hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer. Findings showed that the addition of KEYTRUDA increased the estimated pathologic complete response (pCR) rate nearly threefold in patients with TNBC (60% vs 20%) and in patients with HR+\/HER2- breast cancer (34% vs 13%) compared to standard therapy. Overall, based on Bayesian\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"24 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\\\/\",\"name\":\"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-06-05T06:05:00+00:00\",\"dateModified\":\"2025-11-07T06:26:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/","og_locale":"en_US","og_type":"article","og_title":"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com","og_description":"Data to Be Presented at 2017 ASCO Annual Meeting Include Findings in Patients with Locally Advanced Triple-Negative (TNBC) and Hormone Receptor-Positive\/HER2-Negative (HR+\/HER2-) Breast Cancers Merck (NYSE:MRK), known as MSD outside the United States and Canada, and QuantumLeap Healthcare Collaborative, today announced results from the Phase 2 I-SPY 2 TRIAL investigating KEYTRUDA \u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in combination with standard therapy [paclitaxel followed by doxorubicin and cyclophosphamide (AC)] as a neoadjuvant (pre-operative) treatment for patients with locally advanced triple-negative breast cancer (TNBC) or hormone receptor-positive\/HER2-negative (HR+\/HER2-) breast cancer. Findings showed that the addition of KEYTRUDA increased the estimated pathologic complete response (pCR) rate nearly threefold in patients with TNBC (60% vs 20%) and in patients with HR+\/HER2- breast cancer (34% vs 13%) compared to standard therapy. Overall, based on Bayesian","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:26+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"24 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/","name":"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-06-05T06:05:00+00:00","dateModified":"2025-11-07T06:26:26+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/new-data-from-phase-2-i-spy-2-trial-shows-improved-outcomes-with-combination-of-mercks-keytruda-pembrolizumab-plus-standard-neoadjuvant-therapy-in-patients-with-high-risk-breast-cance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"New Data From Phase 2 I-SPY 2 TRIAL Shows Improved Outcomes with Combination of Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) Plus Standard Neoadjuvant Therapy in Patients with High-Risk Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"78dff630-6c8c-4d27-b2bd-34f2f8563dc0","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2017\/06\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2017\/06\/1\/Quantum-Leap-Logo.jpg","size":"16394","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/New-Data-From-Phase-2-I-SPY-2-TRIAL-Shows-Improved-Outcomes-with-Combination-of-Mercks-KEYTRUDA-pembrolizumab-Plus-Standard-Neoadjuva-NCQ73.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745532","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":2,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745532\/revisions"}],"predecessor-version":[{"id":3674889,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745532\/revisions\/3674889"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745532"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745532"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}